Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 10, 2007, Pages 1604-1609

  Beuthien Baumann, B ^a   Strumpf, A ^a   Zessin, J ^b   Bredow, J ^a   Kotzerke, J ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

Author keywords

3 O methyl 6 18F fluoro DOPA; 18F DOPA; 18F fluorodeoxyglucose; Medullary thyroid carcinoma; Positron emission tomography

Indexed keywords

CALCITONIN; DIHYDROXYPHENYLALANINE 3 O METHYL 6 FLUORODEOXYGLUCOSE F 18; DOPA; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ABDOMEN; ADULT; AGED; ARTICLE; BONE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; HISTOLOGY; HUMAN; INTERMETHOD COMPARISON; LIVER; MALE; MEDIASTINUM; METASTASIS; NECK; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; THYROID MEDULLARY CARCINOMA;

ADULT; AGED; CARCINOMA, MEDULLARY; DIHYDROXYPHENYLALANINE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

EID: 34748868457     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0425-2     Document Type: Article

References (17)

1. Dralle H. Lymph node dissection and medullary thyroid carcinoma. Br J Surg 2002;89:1073-5.
2. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 2001;28:1671-6.
3. Brandt-Mainz K, Muller SP, Gorges R, Saller B, Bockisch A. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 2000;27:490-6.
4. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 2002;43:66-71.
5. 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 2004;11:786-94.
6. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 2001;28:64-71.
7. 18F-fluoro-L-dopa, a new tumor imaging agent: investigation of transport mechanism in vitro. J Nucl Med 2004;45:2116-22.
8. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432-45.
9. 18F]fluoro-l-DOPA and its evaluation in brain tumour imaging. Eur J Nucl Med Mol Imaging 2003;30:1004-8.
10. 18F]fluoro-2-deoxy-D-glucose. Appl Radiat Isot 1996;47:61-6.
11. 18F]fluoro-L-DOPA preparation: precursor synthesis, preparative HPLC purification and determination of radiochemical purity. Nucl Med Biol 2002;29:477-81.
12. 18F]fluoro-L-DOPA. Appl Radiat Isot 2003;58:575-8.
13. Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468-72.
14. Grunwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547-52.
15. Zoller M, Kohlfuerst S, Igerc I, Kresnik E, Gallowitsch HJ, Gomez I, et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? Eur J Nucl Med Mol Imaging 2006.
16. Sampaio-Maia B, Serrao MP, Soares-da-Silva P. Regulatory pathways and uptake of L-DOPA by capillary cerebral endothelial cells, astrocytes, and neuronal cells. Am J Physiol Cell Physiol 2001; 280: C333-42.
17. 18F DOPA whole body PET-initial results. Radiology 2002;222:507-12.